Dianthus Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2015-01-01
- Employees
- 53
- Market Cap
- -
- Website
- https://www.magentatx.com
- Introduction
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Dianthus Therapeutics
- Target Recruit Count
- 480
- Registration Number
- NCT06858579
- Locations
- 🇺🇸
Clinical Study Site, Sugar Land, Texas, United States
🇺🇸Texas Locations, Houston, Texas, United States
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Dianthus Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT06537999
- Locations
- 🇵🇱
Clinical Study Site, Katowice, Poland
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Dianthus Therapeutics
- Target Recruit Count
- 65
- Registration Number
- NCT06282159
- Locations
- 🇺🇸
Clincal Study Site, Tampa, Florida, United States
🇺🇸Clinical Study Site #2, Houston, Texas, United States
🇸🇪Clinical Study Site, Malmö, Sweden
Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
- Conditions
- MyelodysplasiaAcute Myeloid Leukemia
- Interventions
- Biological: MGTA-117
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Magenta Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05223699
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456
- Conditions
- Inherited Metabolic Disorders (IMD)
- Interventions
- Other: Safety and efficacy assessments
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Magenta Therapeutics, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04008849
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Magenta Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03406962
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States